Processing your payment...
Please do not close your browser.

Drugs for Herpes Labialis (Oral Herpes) Market - Growth, Trends And Forecast (2022 - 2027) By Types, By Application, By Regions and By Key Players: GSK, Novartis, Teva, Mylan

08 Jan, 2020 | 119 Pages
Shares
facebook sharing button
linkedin sharing button
twitter sharing button
sharethis sharing button

Acknowledging the kind of traction gained by this market, recently published a study report by industry data analytics asserts the global size is projected to accrue voluminously by 2027 registering a phenomenal CAGR of 5.6% during the review period (2022 to 2027)



Drugs for Herpes Labialis (Oral Herpes) Market Overview



Herpes labialis is a viral contagion caused by the herpes simplex virus 1 (HSV-1) this is usually related to wounds due to cold or herpes simplex virus 2 (HSV-2). Herpes labialis usually happens due to bumps of lips and around the facemask area near the mouth.



Mostly the infection of herpes labialis occurs in childhood and to a certain extent is inactive in the anxious system. However, serious health penalties are seen between new-born babies or people who are immunosuppressed are affected. Drugs for Herpes virus Labialis (Oral Herpes) Market study report delivers a close watch on leading competitors with planned examination, micro and macro market trend and scenarios, pricing analysis and a holistic impression of the market states in the estimate period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and physical examination. Further, key players, major collaborations, merger & attainments along with swerving innovation and business rules are studied in the report.



Who are the Major Players in Drugs for Herpes Labialis (Oral Herpes) Market?



Top Key players in the Drugs for Herpes Labialis (Oral Herpes) Market have been identified through secondary research, and their market shares have been determined through primary and secondary research. The companies referred in the market research report includes GSK, Novartis, Teva, Mylan, Cadila, Apotex, Daewoong Pharmaceutical, Livzon, Luoxin, Med shine, Bayer (Campho Phenique), Blistex, Kelun, Hikma, Haiwang, Carmex, Cipher and others.



Industry News -



Apr 26, 2022: GlaxoSmithKline Pharmaceuticals has launched Trelegy Ellipta for Chronic Obstructive Pulmonary Disease (COPD) patients. Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is the first once daily single-inhaler triple therapy (SITT) in India for COPD patients.



29 April 2022: SK bioscience and GSK announced submission of a biologics license application for SKYCovione™ a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s pandemic adjuvant, to the Korean Ministry of Food and Drug Safety (KMFDS) following positive Phase III clinical data.



What are the major Applications, Types and Regions for Drugs for Herpes Labialis (Oral Herpes) Market?



Drugs for Herpes Labialis (Oral Herpes) Market is segmented based on the type, applications, companies and regions.



By Type, Drugs for Herpes Labialis (Oral Herpes) Market has been segmented into 




  • Aciclovir

  • Valacyclovir

  • Famciclovir

  • Docosanol

  • Other



The end user’s industry application on Drugs for Herpes Labialis (Oral Herpes) Market is, 




  • External Use

  • Oral

  • Injection



Regional Analysis -



The global drugs for herpes labialis (oral herpes) market segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is a promising region for the market. The market is this region constituted a 4.9% share of the global market in 2022. The market in the region is projected to expand at a CAGR of during the forecast period due to the increase in the demand for drugs for herpes labialis, the presence of a mature medicinal infrastructure for R&D activities, and the presence of major players in this region. The market in Asia Pacific is projected to expand at a CAGR of due to augmented administration spending, rising FDI rules, and growing occurrences of the herpes labialis in the region.




  • North America


    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  •       Rest of the World

    • Middle East & Africa

    • Latin America





What is our Drugs for Herpes Labialis (Oral Herpes) Market report scope?























































Report Attributes



Report Details



Forecast Period 2022 to 2028 CAGR



CAGR of 5.6% during the review period (2022 to 2027).



By Type




  • Acyclovir

  • Valacyclovir

  • Famciclovir

  • Docosanol

  • Other



By Application



 




  • External Use

  • Oral

  • Injection

  •  



By Companies



GSK, Novartis, Teva, Mylan, Cadila, Apotex, Daewoong Pharmaceutical, Livzon, Luoxin, Med shine, Bayer (Campho Phenique), Blistex, Kelun, Hikma, Haiwang, Carmex



Regions Covered




  • North America

  • Europe

  • Asia-Pacific

  • Rest of the World



Countries Covered




  • US

  • Canada

  • Germany

  • France

  • UK

  • Italy

  • Spain

  • Rest of Europe

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific

  • Middle East & Africa

  • Latin America



Base Year



2022



Historical Year



2017 to 2021



Forecast Year



2022 to 2027



Number of Pages



 



      119



 



Customization Available



Yes, the report can be customized as per your needs




 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



Key Takeaways from this Drugs for Herpes Labialis (Oral Herpes) Report




  • Evaluate Drugs for Herpes Labialis (Oral Herpes) market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level - for product types, end use applications and by different industry verticals.

  • Understand the different dynamics influencing the market - key driving factors, challenges and hidden opportunities.

  • Get in-depth insights on your competitor performance - market shares, strategies, financial benchmarking, product benchmarking, SWOT and more.

  • Analyze the sales and distribution channels across key geographies to improve top-line revenues.

  • Understand the industry supply chain with a deep dive on the value augmentation at each step, in order to optimize value and bring efficiencies in your processes.

  • Get a quick outlook on the Drugs for Herpes Labialis (Oral Herpes) market entropy - M&A's, deals, partnerships, product launches of all key players for the past 4 years.

  • Evaluate the supply-demand gaps, import-export statistics and regulatory landscape for more than top 20 countries globally for the market.



All our reports are customizable to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report to your needs.



Frequently Asked Question -



What is the study period of this market?



The Drugs for Herpes Labialis (Oral Herpes) Market is studied from 2022-2027.



Who are the prominent players in the Drugs for Herpes Labialis (Oral Herpes) Market?



Mylan, Cadila, Apotex, Daewoong Pharmaceutical, Livzon, Luoxin, Med shine, Bayer (Campho Phenique)



Which region held the largest share in the Drugs for Herpes Labialis (Oral Herpes) Market?



United States, Europe, China, Japan, Southeast Asia, India and Rest of World



What are the significant types of Drugs for Herpes Labialis (Oral Herpes) Market?



Below 32 Oz , Above 32 Oz



What are the major end-use applications of Drugs for Herpes Labialis (Oral Herpes) Market?



External Use, Oral, Injection


  1. INTRODUCTION

    1. MARKET DEFINATION

    2. MARKET DYNAMICS

    3. MARKET SEGMENTATION

    4. REPORT TIMLINES

    5. KEY STAKEHOLDERS



  2. RESEARCH METHODOLOGY

    1. DATA MINING

      • SECONDARY RESEARCH

      • PRIMARY RESEARCH

      • SUBJECT MATTER EXPERT ADVICE



    2. QUALITY CHECK

    3. FINAL REVIEW

      • DATA TRIANGULATION

      • BOTTOM-UP APPROACH

      • TOP-DOWN APPROACH



    4. RESEARCH FLOW



  3. EXECUTIVE SUMMARY

    1. INTRODUCTION

    2. GLOBAL DRUGS FOR HERPES LABIALIS (ORAL HERPES) MARKET BY TYPE

    3. GLOBAL DRUGS FOR HERPES LABIALIS (ORAL HERPES) MARKET BY APPLICTAION



  4. DRUGS FOR HERPES LABIALIS (ORAL HERPES) MARKET DYNAMICS

    1. DRIVERS

    2. INCREASING LENSMETER MARKET

    3. RESTRAINTS

      • STRINGENT ENVIRONMENTAL REGUALTIONS

      • HIGH COST ON MATERIALS



    4. OPPORTUNITIES

      • LENSMETER MARKETGROWTH



    5. APPLICATION OF DRUGS FOR HERPES LABIALIS (ORAL HERPES) MARKETMARKETIMPACT OF COVID 19



  5. GLOBAL DRUGS FOR HERPES LABIALIS (ORAL HERPES) MARKET, BY TYPE

    1. INTRODUCTION

    2. ACICLOVIR

    3. VALACYCLOVIR

    4. FAMCICLOVIR

    5. DOCOSANOL

    6. OTHER



  6. GLOBAL DRUGS FOR HERPES LABIALIS (ORAL HERPES) MARKET BY APPLICATION

    1. INTRODUCTION

    2. EXTERNAL USE

    3. ORAL

    4. INJECTION



  7. GLOBAL DRUGS FOR HERPES LABIALIS (ORAL HERPES) MARKET BY REGION

    1. NORTH AMERICA

      • US

      • CANADA

      • MEXICO



    2. EUROPE

      • GERMANY

      • FRANCE

      • UK

      • ITALY

      • RUSSIA

      • REST OF EUROPE



    3. APAC

      • CHINA

      • SOUTH KOREA

      • JAPAN

      • INDIA

      • AUSTRALIA

      • ASEAN

      • REST OF APAC



    4. MIDDLE EAST & AFRICA

      • SAUDI ARABIA

      • UAE

      • SOUTH AFRICA

      • TURKEY

      • REST OF MEA



    5. SOUTH AMERICA

      • BRAZIL

      • REST OF MEA

      • ARGENTINA

      • REST OF SOUTH AMERICA





  8. COMPETITIVE LANDSCAPE

    1. MERGERS, ACQUISITIONS, JOINT VENTURES, COLLABORATIONS,

    2. AND AGREEMENTS

      • KEY DEVELOPMENT



    3. MARKET SHARE (%) **/RANKING ANALYSIS

    4. STRATEGIES ADOPTED BY LEADING PLAYERS



  9. COMPANY PROFILES

    • BUSINESS OVERVIEW

    • COMPANY SNAPSHOT

    • PRODUCT BENCHMARKING

    • STRATEGIC INITIATIVES

      1. GSK,

      2. NOVARTIS,

      3. TEVA,

      4. MYLAN,

      5. CADILA,

      6. APOTEX,

      7. DAEWOONG PHARMACEUTICAL,

      8.  LIVZON,

      9. LUOXIN,

      10. MED SHINE,

      11. BAYER (CAMPHO PHENIQUE),

      12. BLISTEX,

      13. KELUN,

      14. HIKMA,

      15. HAIWANG,

      16. CARMEX,

      17. CIPHER AND

      18. OTHERS.





SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

  • Single User License
    $2500
  • Site License
    $3000
  • Global License
    $5000

How can we help you?

Reach us with your research requirements and we shall provide the optimum solution to suit your needs.

Curioust about Multiple Reports?

Discounts available for multiple report purchases.

Contact Us

Our Clients

  • 3M
  • Merck
  • IBM
  • Dow
  • Henkel
  • AirBus
  • Cummins
  • Intel
  • Sony